Study guide

5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods

Key Takeaways Explain This Topic AI

The Copper IUD and 52 mg Levonorgestrel IUS represent the most effective methods of emergency contraception (>99% efficacy) when inserted within 5 days (120 hours) of unprotected coitus, providing concurrent transition to long-term Tier 1 contraception.

Ulipristal acetate (Ella, 30 mg oral SPRM) maintains superior efficacy across the entire 120-hour window compared to oral levonorgestrel, inhibits ovulation even after the LH surge has begun, and remains efficacious in individuals with BMI ≥30 kg/m².

Starting hormonal contraception immediately after ulipristal acetate can reduce its efficacy, so patients wait at least 5 days before starting a hormonal method and then use barrier backup or abstain until 7 days after starting (about 12 days in total).

Barrier methods are the sole contraceptive modality providing protection against sexually transmitted infections; frequent use of the surfactant spermicide nonoxynol-9 induces vaginal mucosal disruption and paradoxically increases HIV acquisition risk.

Fertility awareness-based methods (FABMs) identify the fertile window (sperm survival ~5 days plus ovum survival ~24 hours); the symptothermal method combines cervical mucus monitoring with the post-ovulatory basal body temperature thermal shift (sustained 0.4°F–1.0°F elevation) driven by progesterone.

Last updated: October 2026

Emergency Contraception (EC) Comparative Efficacy Hierarchy

Emergency contraception (EC) provides postcoital pregnancy prevention following unprotected intercourse, sexual assault, or contraceptive failure. EC methods act before implantation; they do not disrupt an established pregnancy and are not abortifacients.

Modality Formulation & Dose Approved Window Mechanism of Action Body Weight & BMI Impact Ongoing Contraception Bridging

Copper IUD (Paragard) 380 mm² copper device Up to 120 hr (5 days) Direct spermicide; sterile endometrial inflammation Most effective (>99.9%) ; unaffected by body weight or BMI Immediate Tier 1 contraception for up to 10–12 years.

52 mg LNG-IUS (Mirena, Liletta) 52 mg levonorgestrel system Up to 120 hr (5 days) Cervical mucus thickening; sterile endometrial inflammation Non-inferior to Copper IUD; highly effective across all BMIs Immediate Tier 1 contraception for up to 8 years.

Ulipristal Acetate (Ella) 30 mg oral tablet Up to 120 hr (5 days) Selective progesterone receptor modulator (SPRM); delays follicular rupture even after LH surge starts Superior efficacy in BMI ≥30 kg/m² vs levonorgestrel Delay hormonal start ≥5 days ; backup until 7 days after starting.

Oral Levonorgestrel (Plan B) 1.5 mg oral tablet (or 0.75 mg q12h x 2) Up to 72 hr (declines 72–120 hr) High-dose progestin; blocks LH surge before it begins May be less effective with BMI ≥30 kg/m²; still better than no EC (UPA or an IUD preferred) Immediate "quick start" permitted; barrier backup for 7 days .

Yuzpe Regimen Combined COCs: 100 mcg EE + 0.5 mg LNG q12h x 2 Up to 72 hr Suppresses LH surge; alters tubal motility Lower efficacy (~75%); high nausea (50%) and emesis (20%) Historical interest; premedicate with oral antiemetics.

  • Post-EC Bridging Protocols
  • Ulipristal Acetate (UPA) Bridging Protocol

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) . If exogenous progestins (from pills, patches, rings, injections, or implants) are started immediately after UPA, competitive binding occurs: the progestin displaces UPA from receptors, neutralizing UPA's emergency contraceptive efficacy while impairing the progestin's contraceptive onset.

The 5-Day Delay Rule: Patients must wait at least 5 full days after taking UPA before initiating or resuming any hormonal contraceptive method.

Backup Contraception: The patient must abstain or strictly utilize barrier methods during the 5-day waiting period plus an additional 7 days of active hormonal contraception (about 12 days in total).

Oral Levonorgestrel Bridging Protocol

Levonorgestrel does not compete antagonistically. Patients can quick-start hormonal contraception immediately on the same day oral levonorgestrel is taken. A backup method is needed for 7 days (2 days for a norethindrone or norgestrel POP).

  • Barrier Methods of Contraception
  • Condoms & STI Protection

External (male) condoms (latex, polyurethane, polyisoprene) and internal (female) condoms (nitrile sheath with retention rings) are the only contraceptive methods providing substantial protection against Sexually Transmitted Infections (STIs) , including HIV, gonorrhea, chlamydia, and trichomoniasis.

Lubricant Compatibility: Latex condoms degrade rapidly when exposed to oil-based lubricants (petroleum jelly, baby oil, mineral oil, lotions), breaking down within 60 seconds. Only water-based or silicone lubricants are safe with latex. Polyurethane and polyisoprene condoms are safe with oil-based lubricants and in latex allergy.

Cervical Barriers: Diaphragms & Cervical Caps

Diaphragms (Caya, Traditional Spring-Loaded): Silicone dome covering the ectocervix, anchored between the posterior fornix and pubic symphysis. Must be used with spermicidal gel. Must remain in place for at least 6 hours post-coitus (dwell time) to ensure sperm immobilization, but must be removed within 24 hours to prevent Toxic Shock Syndrome (TSS). Refitting is required following weight changes of ≥10–15 lbs, term delivery, or pelvic surgery.

Cervical Cap (FemCap): Silicone cup fitting over the cervix via suction. Minimum dwell time is 6 hours; maximum wear time is 48 hours . Efficacy is significantly reduced in parous individuals.

Vaginal pH Modulator Gel (Phexxi)

Lactic acid, citric acid, and potassium bitartrate gel inserted up to 1 hour before each act of intercourse; it keeps vaginal pH acidic so sperm lose motility. Typical-use failure is about 14% per year, it offers no STI protection, and it should be avoided in patients with recurrent urinary tract infections or urinary tract abnormalities (cystitis was a leading adverse event).

Spermicides & Nonoxynol-9 Toxicity

Mechanism: Nonoxynol-9 (N-9) is a surfactant that disrupts sperm cell membranes. Typical failure rate is high (~21–28%).

Mucosal Safety Warning: Nonoxynol-9 does not protect against STIs or HIV . Frequent use (multiple times daily) causes chemical disruption and micro-ulcerations of the vaginal and cervical epithelium. This disruption promotes inflammatory leukocyte recruitment, increasing the risk of HIV transmission . CDC and WHO guidelines strictly contraindicate N-9 use in individuals with, or at risk for, HIV/STIs.

Fertility Awareness-Based Methods (FABMs)

FABMs identify the fertile window based on gamete physiology: sperm survive up to 5 days in fertile cervical mucus, while the unfertilized ovum survives 12–24 hours post-ovulation (a 6-day fertile window).

Lactational Amenorrhea Method (LAM): More than 98% effective while all three conditions hold: amenorrhea since delivery, fully or nearly fully breastfeeding (US MEC 2024: no more than 4 hours between feeds by day and 6 hours at night), and infant younger than 6 months.

Standard Days Method (SDM / CycleBeads): Valid only for women with regular menstrual cycles between 26 and 32 days . Intercourse is avoided (or barrier methods used) on cycle days 8 through 19 inclusive.

TwoDay Method: Based on daily evaluation of cervical secretions. The woman asks: (1) "Did I notice secretions today?" and (2) "Did I notice secretions yesterday?" If secretions are present on either today or yesterday , she is considered fertile. If no secretions are present on both days , pregnancy is unlikely.

Billings Ovulation Method: Tracks vulvar sensation and cervical mucus. Rising follicular estradiol stimulates endocervical crypts to produce clear, stretchy, slippery, lubricative mucus (spinnbarkeit, raw egg white consistency). The "peak day" is the last day of slippery mucus; ovulation occurs within 48 hours of peak mucus. The infertile phase begins on the fourth evening after the peak day.

Symptothermal Method: Combines cervical mucus observation with daily Basal Body Temperature (BBT) taken upon waking before activity. Following ovulation, progesterone secreted by the corpus luteum exerts a thermogenic action on the hypothalamus , causing a sustained thermal shift of 0.4°F to 1.0°F (0.2°C to 0.5°C) . The post-ovulatory infertile phase begins on the evening of the third consecutive day of elevated temperatures above the preceding six baseline temperatures (the "3 over 6" rule).